Malik Kahook
Concepts (455)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 63 | 2025 | 253 | 13.990 |
Why?
| | Intraocular Pressure | 72 | 2025 | 332 | 9.370 |
Why?
| | Glaucoma, Open-Angle | 29 | 2024 | 105 | 6.350 |
Why?
| | Trabecular Meshwork | 23 | 2019 | 74 | 5.140 |
Why?
| | Glaucoma Drainage Implants | 18 | 2022 | 47 | 4.760 |
Why?
| | Antihypertensive Agents | 27 | 2019 | 522 | 4.250 |
Why?
| | Trabeculectomy | 17 | 2025 | 75 | 3.980 |
Why?
| | Preservatives, Pharmaceutical | 12 | 2024 | 28 | 3.690 |
Why?
| | Angiogenesis Inhibitors | 15 | 2021 | 239 | 3.430 |
Why?
| | Ocular Hypertension | 18 | 2024 | 71 | 3.300 |
Why?
| | Conjunctiva | 13 | 2012 | 52 | 3.050 |
Why?
| | Filtering Surgery | 9 | 2016 | 23 | 3.040 |
Why?
| | Ophthalmic Solutions | 18 | 2024 | 82 | 2.960 |
Why?
| | Benzalkonium Compounds | 11 | 2024 | 15 | 2.540 |
Why?
| | Tonometry, Ocular | 24 | 2025 | 104 | 2.370 |
Why?
| | Vascular Endothelial Growth Factor A | 12 | 2021 | 552 | 2.260 |
Why?
| | Phacoemulsification | 14 | 2025 | 123 | 2.210 |
Why?
| | Timolol | 8 | 2019 | 14 | 2.130 |
Why?
| | Prostaglandins F, Synthetic | 8 | 2014 | 9 | 2.130 |
Why?
| | Ciliary Body | 12 | 2025 | 40 | 1.990 |
Why?
| | Glaucoma, Neovascular | 5 | 2015 | 10 | 1.640 |
Why?
| | Cloprostenol | 9 | 2013 | 13 | 1.620 |
Why?
| | Laser Coagulation | 10 | 2025 | 80 | 1.520 |
Why?
| | Lens Implantation, Intraocular | 7 | 2020 | 80 | 1.300 |
Why?
| | Cataract Extraction | 6 | 2020 | 120 | 1.280 |
Why?
| | Cataract | 8 | 2020 | 238 | 1.270 |
Why?
| | Prosthesis Implantation | 8 | 2022 | 156 | 1.260 |
Why?
| | Antibodies, Monoclonal | 11 | 2011 | 1514 | 1.250 |
Why?
| | Optic Disk | 7 | 2025 | 53 | 1.230 |
Why?
| | Cornea | 8 | 2013 | 156 | 1.200 |
Why?
| | Tomography, Optical Coherence | 7 | 2025 | 277 | 1.200 |
Why?
| | Retinal Ganglion Cells | 6 | 2025 | 123 | 1.150 |
Why?
| | Drug Delivery Systems | 7 | 2019 | 381 | 1.130 |
Why?
| | Blister | 4 | 2012 | 39 | 1.130 |
Why?
| | Travoprost | 10 | 2014 | 13 | 1.070 |
Why?
| | Stents | 5 | 2021 | 570 | 1.070 |
Why?
| | Nerve Fibers | 4 | 2012 | 105 | 1.030 |
Why?
| | Medication Adherence | 4 | 2016 | 540 | 1.020 |
Why?
| | Optic Nerve Diseases | 3 | 2025 | 49 | 0.990 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 192 | 0.990 |
Why?
| | Humans | 135 | 2026 | 147306 | 0.970 |
Why?
| | Sulfonamides | 4 | 2018 | 596 | 0.960 |
Why?
| | Glaucoma, Angle-Closure | 5 | 2018 | 23 | 0.950 |
Why?
| | Endoscopy | 8 | 2025 | 322 | 0.950 |
Why?
| | Lenses, Intraocular | 4 | 2020 | 49 | 0.930 |
Why?
| | Corneal Diseases | 2 | 2024 | 48 | 0.920 |
Why?
| | Lens, Crystalline | 2 | 2020 | 136 | 0.920 |
Why?
| | Capsulorhexis | 2 | 2016 | 9 | 0.910 |
Why?
| | Polymers | 5 | 2011 | 486 | 0.870 |
Why?
| | Eye | 6 | 2013 | 112 | 0.870 |
Why?
| | Macular Degeneration | 4 | 2010 | 196 | 0.840 |
Why?
| | Photons | 4 | 2016 | 67 | 0.840 |
Why?
| | Microscopy | 4 | 2018 | 148 | 0.840 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 109 | 0.810 |
Why?
| | Dry Eye Syndromes | 1 | 2024 | 56 | 0.780 |
Why?
| | Pilocarpine | 2 | 2025 | 16 | 0.780 |
Why?
| | Vision Disorders | 4 | 2025 | 179 | 0.770 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2014 | 91 | 0.750 |
Why?
| | Cell Survival | 8 | 2013 | 1111 | 0.750 |
Why?
| | Brimonidine Tartrate | 3 | 2018 | 10 | 0.720 |
Why?
| | Aged | 45 | 2025 | 26516 | 0.710 |
Why?
| | Bevacizumab | 12 | 2021 | 168 | 0.700 |
Why?
| | Drug Packaging | 4 | 2015 | 41 | 0.700 |
Why?
| | Visual Acuity | 12 | 2025 | 498 | 0.680 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 669 | 0.670 |
Why?
| | Antibodies, Monoclonal, Humanized | 12 | 2011 | 1005 | 0.650 |
Why?
| | Thiazines | 2 | 2018 | 13 | 0.640 |
Why?
| | Laser Therapy | 3 | 2016 | 146 | 0.640 |
Why?
| | Spectrum Analysis, Raman | 4 | 2013 | 38 | 0.630 |
Why?
| | Epithelium, Corneal | 2 | 2010 | 41 | 0.630 |
Why?
| | Visual Fields | 4 | 2025 | 116 | 0.620 |
Why?
| | Prosthesis Design | 4 | 2016 | 363 | 0.620 |
Why?
| | Thiophenes | 2 | 2011 | 117 | 0.610 |
Why?
| | Sclera | 7 | 2015 | 38 | 0.610 |
Why?
| | Drug Combinations | 9 | 2017 | 399 | 0.600 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 8 | 2016 | 63 | 0.600 |
Why?
| | Benzoates | 1 | 2019 | 51 | 0.570 |
Why?
| | beta-Alanine | 1 | 2019 | 25 | 0.570 |
Why?
| | Imaging, Three-Dimensional | 5 | 2016 | 587 | 0.550 |
Why?
| | Middle Aged | 43 | 2025 | 36821 | 0.550 |
Why?
| | rho-Associated Kinases | 1 | 2019 | 82 | 0.550 |
Why?
| | Aged, 80 and over | 21 | 2025 | 8432 | 0.540 |
Why?
| | Drug Monitoring | 3 | 2016 | 402 | 0.540 |
Why?
| | Ranibizumab | 8 | 2021 | 21 | 0.540 |
Why?
| | Cells, Cultured | 12 | 2015 | 4170 | 0.540 |
Why?
| | Ophthalmology | 5 | 2024 | 121 | 0.520 |
Why?
| | Ocular Hypotension | 4 | 2022 | 10 | 0.520 |
Why?
| | Retinal Pigment Epithelium | 4 | 2015 | 80 | 0.510 |
Why?
| | Prostaglandins F | 3 | 2011 | 15 | 0.510 |
Why?
| | Equipment Design | 6 | 2018 | 527 | 0.510 |
Why?
| | Treatment Outcome | 20 | 2025 | 11947 | 0.500 |
Why?
| | Male | 57 | 2025 | 73954 | 0.500 |
Why?
| | Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.490 |
Why?
| | Patient Compliance | 4 | 2018 | 591 | 0.480 |
Why?
| | Epithelial Cells | 3 | 2011 | 1141 | 0.470 |
Why?
| | Retrospective Studies | 28 | 2025 | 17561 | 0.460 |
Why?
| | Prospective Studies | 14 | 2021 | 8166 | 0.460 |
Why?
| | Female | 54 | 2025 | 80081 | 0.450 |
Why?
| | Intravitreal Injections | 6 | 2021 | 73 | 0.450 |
Why?
| | Oxidative Stress | 2 | 2013 | 1368 | 0.440 |
Why?
| | Reminder Systems | 1 | 2016 | 148 | 0.440 |
Why?
| | Mitomycin | 3 | 2016 | 33 | 0.440 |
Why?
| | Wound Healing | 3 | 2012 | 361 | 0.440 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 211 | 0.430 |
Why?
| | Uveitis | 3 | 2022 | 151 | 0.430 |
Why?
| | Motivational Interviewing | 1 | 2016 | 122 | 0.430 |
Why?
| | Pharmaceutical Preparations | 2 | 2019 | 172 | 0.430 |
Why?
| | Circadian Rhythm | 3 | 2023 | 514 | 0.420 |
Why?
| | Iris | 4 | 2013 | 23 | 0.400 |
Why?
| | Injections | 6 | 2010 | 200 | 0.390 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5478 | 0.390 |
Why?
| | Behavior Therapy | 1 | 2016 | 297 | 0.390 |
Why?
| | Pyruvates | 1 | 2013 | 23 | 0.390 |
Why?
| | Cell Count | 4 | 2021 | 321 | 0.390 |
Why?
| | Administration, Topical | 5 | 2016 | 156 | 0.390 |
Why?
| | Patient Preference | 1 | 2016 | 225 | 0.390 |
Why?
| | Stainless Steel | 2 | 2010 | 19 | 0.390 |
Why?
| | Porphyrins | 1 | 2013 | 16 | 0.380 |
Why?
| | Pseudophakia | 2 | 2018 | 21 | 0.380 |
Why?
| | Anterior Chamber | 2 | 2012 | 26 | 0.380 |
Why?
| | Triamcinolone Acetonide | 2 | 2014 | 20 | 0.380 |
Why?
| | Perception | 3 | 2021 | 378 | 0.370 |
Why?
| | Goblet Cells | 2 | 2012 | 22 | 0.370 |
Why?
| | Photosensitizing Agents | 1 | 2013 | 42 | 0.370 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2026 | 794 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2011 | 2030 | 0.360 |
Why?
| | Rabbits | 7 | 2015 | 654 | 0.360 |
Why?
| | Health Behavior | 2 | 2015 | 799 | 0.360 |
Why?
| | Eye Diseases | 3 | 2024 | 98 | 0.350 |
Why?
| | Drugs, Generic | 1 | 2011 | 28 | 0.340 |
Why?
| | Vitreous Body | 5 | 2010 | 118 | 0.340 |
Why?
| | Telemedicine | 1 | 2021 | 978 | 0.340 |
Why?
| | Surgically-Created Structures | 1 | 2011 | 2 | 0.330 |
Why?
| | Drug Therapy | 1 | 2011 | 84 | 0.330 |
Why?
| | NADP | 1 | 2011 | 52 | 0.330 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Blood Pressure | 2 | 2017 | 1785 | 0.320 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2010 | 20 | 0.320 |
Why?
| | Tissue Adhesives | 2 | 2010 | 21 | 0.320 |
Why?
| | Endothelins | 1 | 2010 | 61 | 0.310 |
Why?
| | Prescription Drugs | 1 | 2011 | 111 | 0.310 |
Why?
| | Choroid | 1 | 2010 | 80 | 0.310 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 63 | 0.300 |
Why?
| | Dexamethasone | 1 | 2012 | 368 | 0.300 |
Why?
| | Quinoxalines | 1 | 2009 | 65 | 0.290 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 338 | 0.290 |
Why?
| | Depressive Disorder | 1 | 2012 | 379 | 0.280 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1049 | 0.280 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 234 | 0.280 |
Why?
| | Anxiety Disorders | 1 | 2012 | 376 | 0.280 |
Why?
| | Adult | 21 | 2025 | 41406 | 0.280 |
Why?
| | Artificial Intelligence | 2 | 2025 | 389 | 0.280 |
Why?
| | Surgical Wound Dehiscence | 1 | 2008 | 22 | 0.270 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2020 | 55 | 0.270 |
Why?
| | Particulate Matter | 2 | 2011 | 329 | 0.270 |
Why?
| | Collagen | 5 | 2016 | 460 | 0.270 |
Why?
| | Primary Health Care | 2 | 2009 | 1760 | 0.270 |
Why?
| | Reproducibility of Results | 8 | 2025 | 3448 | 0.270 |
Why?
| | Aqueous Humor | 4 | 2016 | 41 | 0.260 |
Why?
| | Postoperative Period | 5 | 2025 | 351 | 0.260 |
Why?
| | Cognition Disorders | 1 | 2012 | 551 | 0.260 |
Why?
| | Neovascularization, Pathologic | 4 | 2013 | 287 | 0.260 |
Why?
| | Retinoschisis | 1 | 2006 | 2 | 0.250 |
Why?
| | Software | 1 | 2012 | 683 | 0.250 |
Why?
| | Endothelium, Corneal | 2 | 2021 | 19 | 0.240 |
Why?
| | Fluorescence | 3 | 2011 | 161 | 0.240 |
Why?
| | Trypan Blue | 1 | 2006 | 5 | 0.240 |
Why?
| | Self Administration | 1 | 2007 | 122 | 0.240 |
Why?
| | Animals | 22 | 2016 | 38417 | 0.240 |
Why?
| | Coloring Agents | 1 | 2006 | 90 | 0.240 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2006 | 3 | 0.230 |
Why?
| | Optic Nerve | 1 | 2006 | 67 | 0.230 |
Why?
| | Administration, Ophthalmic | 2 | 2019 | 16 | 0.230 |
Why?
| | Eye Injuries | 2 | 2006 | 53 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1431 | 0.230 |
Why?
| | Visual Field Tests | 2 | 2024 | 32 | 0.230 |
Why?
| | Iridectomy | 1 | 2005 | 2 | 0.230 |
Why?
| | Contact Lenses | 3 | 2020 | 13 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2006 | 40 | 0.230 |
Why?
| | Postoperative Complications | 7 | 2021 | 3022 | 0.230 |
Why?
| | Pseudotumor Cerebri | 1 | 2006 | 32 | 0.220 |
Why?
| | Monitoring, Physiologic | 2 | 2018 | 290 | 0.220 |
Why?
| | Acrylic Resins | 2 | 2016 | 48 | 0.220 |
Why?
| | Histological Techniques | 2 | 2018 | 39 | 0.220 |
Why?
| | Glucocorticoids | 2 | 2016 | 537 | 0.220 |
Why?
| | Visual Pathways | 1 | 2025 | 61 | 0.220 |
Why?
| | Cadaver | 3 | 2016 | 316 | 0.210 |
Why?
| | Geographic Atrophy | 1 | 2026 | 103 | 0.210 |
Why?
| | Pilot Projects | 5 | 2018 | 1912 | 0.200 |
Why?
| | Alkylating Agents | 3 | 2016 | 24 | 0.200 |
Why?
| | United States Food and Drug Administration | 2 | 2015 | 208 | 0.200 |
Why?
| | Retina | 3 | 2016 | 331 | 0.190 |
Why?
| | Case-Control Studies | 5 | 2024 | 3660 | 0.190 |
Why?
| | Drug Stability | 3 | 2011 | 169 | 0.190 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 6164 | 0.190 |
Why?
| | Prostaglandins, Synthetic | 2 | 2013 | 5 | 0.180 |
Why?
| | Titanium | 2 | 2014 | 74 | 0.180 |
Why?
| | ROC Curve | 1 | 2024 | 626 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 324 | 0.170 |
Why?
| | Nervous System Diseases | 1 | 2024 | 288 | 0.170 |
Why?
| | Drug Storage | 2 | 2011 | 53 | 0.170 |
Why?
| | Heart Rate | 2 | 2017 | 860 | 0.170 |
Why?
| | Self Report | 2 | 2016 | 887 | 0.170 |
Why?
| | Cross-Sectional Studies | 7 | 2022 | 6011 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2020 | 73 | 0.150 |
Why?
| | Young Adult | 8 | 2019 | 14437 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 137 | 0.150 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 17 | 0.140 |
Why?
| | Attitude | 1 | 2021 | 260 | 0.140 |
Why?
| | Limbus Corneae | 2 | 2015 | 8 | 0.140 |
Why?
| | Postoperative Care | 3 | 2025 | 299 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2020 | 142 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 122 | 0.140 |
Why?
| | Medication Errors | 2 | 2015 | 85 | 0.130 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 27 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3980 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 252 | 0.130 |
Why?
| | Fibroblasts | 2 | 2013 | 1040 | 0.130 |
Why?
| | Tropicamide | 1 | 2016 | 2 | 0.120 |
Why?
| | Double-Blind Method | 2 | 2019 | 2080 | 0.120 |
Why?
| | Mydriatics | 1 | 2016 | 10 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2020 | 249 | 0.120 |
Why?
| | Phenylephrine | 1 | 2016 | 74 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 222 | 0.120 |
Why?
| | Delayed-Action Preparations | 2 | 2018 | 191 | 0.110 |
Why?
| | Endophthalmitis | 1 | 2016 | 46 | 0.110 |
Why?
| | Fibrosis | 1 | 2018 | 568 | 0.110 |
Why?
| | Artificial Lens Implant Migration | 1 | 2015 | 3 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 654 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 754 | 0.110 |
Why?
| | Swine | 3 | 2013 | 828 | 0.110 |
Why?
| | Hyaluronic Acid | 2 | 2008 | 226 | 0.110 |
Why?
| | Alloys | 1 | 2015 | 37 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 490 | 0.110 |
Why?
| | Surgical Flaps | 1 | 2016 | 142 | 0.110 |
Why?
| | Capsule Opacification | 1 | 2015 | 22 | 0.110 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1281 | 0.110 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 10 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1107 | 0.110 |
Why?
| | Biodegradable Plastics | 1 | 2014 | 3 | 0.110 |
Why?
| | Endpoint Determination | 1 | 2015 | 85 | 0.110 |
Why?
| | Micelles | 1 | 2014 | 39 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2021 | 886 | 0.110 |
Why?
| | Viscosupplements | 1 | 2014 | 11 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1046 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2012 | 2529 | 0.100 |
Why?
| | Nickel | 1 | 2014 | 63 | 0.100 |
Why?
| | Autopsy | 2 | 2011 | 96 | 0.100 |
Why?
| | Societies, Medical | 2 | 2015 | 914 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 895 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 355 | 0.100 |
Why?
| | Disease Progression | 3 | 2024 | 2892 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 347 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 961 | 0.100 |
Why?
| | Models, Psychological | 1 | 2015 | 295 | 0.100 |
Why?
| | Gonioscopy | 1 | 2013 | 11 | 0.100 |
Why?
| | Protective Agents | 1 | 2013 | 43 | 0.090 |
Why?
| | Macular Edema | 2 | 2016 | 49 | 0.090 |
Why?
| | Tissue Scaffolds | 1 | 2015 | 221 | 0.090 |
Why?
| | Antimetabolites | 1 | 2012 | 21 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2014 | 149 | 0.090 |
Why?
| | Photochemotherapy | 1 | 2013 | 39 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2019 | 886 | 0.090 |
Why?
| | Manifest Anxiety Scale | 1 | 2012 | 3 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2016 | 718 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1720 | 0.090 |
Why?
| | Melanins | 1 | 2011 | 16 | 0.090 |
Why?
| | Quality of Life | 1 | 2024 | 3246 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2014 | 617 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 948 | 0.090 |
Why?
| | Needles | 1 | 2012 | 63 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 56 | 0.090 |
Why?
| | Fluoresceins | 1 | 2011 | 48 | 0.080 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 342 | 0.080 |
Why?
| | Elastin | 1 | 2011 | 78 | 0.080 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2011 | 36 | 0.080 |
Why?
| | Biocompatible Materials | 1 | 2015 | 432 | 0.080 |
Why?
| | Cell Death | 1 | 2013 | 383 | 0.080 |
Why?
| | Self Efficacy | 1 | 2015 | 423 | 0.080 |
Why?
| | Lasers | 1 | 2011 | 128 | 0.080 |
Why?
| | Dextrans | 1 | 2011 | 84 | 0.080 |
Why?
| | Psychometrics | 1 | 2015 | 739 | 0.080 |
Why?
| | Immunoglobulin Fragments | 1 | 2010 | 11 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 133 | 0.080 |
Why?
| | Memory Disorders | 1 | 2012 | 198 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 481 | 0.080 |
Why?
| | Fovea Centralis | 1 | 2010 | 24 | 0.080 |
Why?
| | Retreatment | 1 | 2010 | 80 | 0.080 |
Why?
| | Silicone Oils | 1 | 2011 | 38 | 0.080 |
Why?
| | Equipment Safety | 1 | 2010 | 38 | 0.080 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 37 | 0.080 |
Why?
| | Microscopy, Electron, Scanning | 4 | 2015 | 196 | 0.080 |
Why?
| | Physician-Patient Relations | 1 | 2015 | 594 | 0.080 |
Why?
| | Chromatography, Gel | 1 | 2010 | 131 | 0.080 |
Why?
| | Immunoglobulin Light Chains | 1 | 2010 | 52 | 0.080 |
Why?
| | Torque | 1 | 2010 | 82 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2010 | 86 | 0.080 |
Why?
| | Motivation | 1 | 2015 | 616 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2012 | 240 | 0.080 |
Why?
| | Molecular Weight | 1 | 2010 | 313 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 332 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 205 | 0.080 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 79 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 6042 | 0.070 |
Why?
| | Aptamers, Nucleotide | 1 | 2010 | 88 | 0.070 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 593 | 0.070 |
Why?
| | Cell Separation | 1 | 2010 | 306 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 342 | 0.070 |
Why?
| | Tissue Donors | 1 | 2012 | 427 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 322 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 800 | 0.070 |
Why?
| | Suture Techniques | 1 | 2010 | 138 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2009 | 138 | 0.070 |
Why?
| | Vasoconstriction | 1 | 2010 | 216 | 0.070 |
Why?
| | Risk Assessment | 2 | 2020 | 3784 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 409 | 0.070 |
Why?
| | Communication | 1 | 2015 | 989 | 0.070 |
Why?
| | Ocular Motility Disorders | 1 | 2009 | 42 | 0.070 |
Why?
| | Choroidal Neovascularization | 1 | 2009 | 56 | 0.070 |
Why?
| | Retinal Vein Occlusion | 1 | 2008 | 14 | 0.070 |
Why?
| | Amphetamine-Related Disorders | 1 | 2009 | 53 | 0.070 |
Why?
| | Chondroitin | 1 | 2008 | 6 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2011 | 575 | 0.070 |
Why?
| | Fluorescein | 1 | 2008 | 24 | 0.070 |
Why?
| | Microvilli | 1 | 2008 | 75 | 0.070 |
Why?
| | Methamphetamine | 1 | 2009 | 75 | 0.070 |
Why?
| | Risk Factors | 3 | 2018 | 11017 | 0.070 |
Why?
| | Rupture | 1 | 2008 | 91 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 849 | 0.070 |
Why?
| | Lymphocyte Count | 1 | 2008 | 165 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 975 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 840 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 184 | 0.060 |
Why?
| | Cell Line | 1 | 2013 | 2832 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7173 | 0.060 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 1145 | 0.060 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 187 | 0.060 |
Why?
| | Mice | 6 | 2016 | 18493 | 0.060 |
Why?
| | Mice, Inbred BALB C | 3 | 2015 | 1266 | 0.060 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.060 |
Why?
| | United States | 5 | 2022 | 16313 | 0.060 |
Why?
| | Perioperative Care | 2 | 2019 | 231 | 0.060 |
Why?
| | Uveal Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Conjunctivitis | 1 | 2006 | 30 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2921 | 0.060 |
Why?
| | Scleral Buckling | 1 | 2006 | 16 | 0.060 |
Why?
| | Glucosyltransferases | 1 | 2006 | 4 | 0.060 |
Why?
| | Sweat Gland Neoplasms | 1 | 2006 | 8 | 0.060 |
Why?
| | Lymphocytes | 1 | 2008 | 378 | 0.060 |
Why?
| | Sutures | 1 | 2006 | 66 | 0.060 |
Why?
| | Eyelid Neoplasms | 1 | 2006 | 11 | 0.060 |
Why?
| | Motorcycles | 1 | 2005 | 7 | 0.060 |
Why?
| | Geniculate Bodies | 1 | 2025 | 22 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 176 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Fundus Oculi | 1 | 2025 | 89 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 146 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 2017 | 0.050 |
Why?
| | Forecasting | 1 | 2007 | 391 | 0.050 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2006 | 77 | 0.050 |
Why?
| | Treatment Failure | 1 | 2006 | 360 | 0.050 |
Why?
| | Syndrome | 1 | 2006 | 385 | 0.050 |
Why?
| | Prevalence | 1 | 2012 | 2889 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2023 | 2133 | 0.050 |
Why?
| | Vietnam | 1 | 2023 | 27 | 0.050 |
Why?
| | Accidents, Traffic | 1 | 2005 | 195 | 0.050 |
Why?
| | Optical Imaging | 2 | 2015 | 63 | 0.050 |
Why?
| | Materials Testing | 2 | 2015 | 346 | 0.050 |
Why?
| | Sleep | 2 | 2023 | 895 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 334 | 0.050 |
Why?
| | Incidence | 1 | 2010 | 2954 | 0.050 |
Why?
| | Injections, Intraocular | 2 | 2014 | 14 | 0.050 |
Why?
| | Neurology | 1 | 2024 | 117 | 0.050 |
Why?
| | Photography | 1 | 2023 | 120 | 0.050 |
Why?
| | Reoperation | 1 | 2006 | 644 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2136 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2454 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1072 | 0.040 |
Why?
| | Age Factors | 1 | 2009 | 3372 | 0.040 |
Why?
| | Manometry | 1 | 2021 | 98 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4384 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 329 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2006 | 1171 | 0.040 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2018 | 14 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 150 | 0.030 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.030 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Drug Resistance | 1 | 2018 | 145 | 0.030 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.030 |
Why?
| | Adolescent | 4 | 2019 | 22826 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1868 | 0.030 |
Why?
| | Pupil | 1 | 2016 | 22 | 0.030 |
Why?
| | Rats | 2 | 2016 | 5613 | 0.030 |
Why?
| | Biomimetics | 1 | 2016 | 41 | 0.030 |
Why?
| | Nerve Regeneration | 1 | 2016 | 58 | 0.030 |
Why?
| | Neurites | 1 | 2016 | 51 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2016 | 44 | 0.030 |
Why?
| | Prednisolone | 1 | 2016 | 67 | 0.030 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.030 |
Why?
| | Slit Lamp | 1 | 2015 | 3 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 70 | 0.030 |
Why?
| | Opossums | 1 | 2015 | 9 | 0.030 |
Why?
| | Medical Device Legislation | 1 | 2015 | 3 | 0.030 |
Why?
| | Anterior Eye Segment | 1 | 2015 | 10 | 0.030 |
Why?
| | Device Approval | 1 | 2015 | 19 | 0.030 |
Why?
| | Color | 1 | 2015 | 81 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 2016 | 153 | 0.030 |
Why?
| | Academies and Institutes | 1 | 2015 | 61 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2015 | 124 | 0.030 |
Why?
| | Membrane Lipids | 1 | 2015 | 82 | 0.030 |
Why?
| | Axons | 1 | 2016 | 206 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2014 | 23 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 149 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 96 | 0.030 |
Why?
| | Drug Utilization | 1 | 2015 | 171 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4130 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 394 | 0.030 |
Why?
| | Quality Control | 1 | 2014 | 161 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 177 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 196 | 0.020 |
Why?
| | Corneal Stroma | 1 | 2013 | 24 | 0.020 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2013 | 29 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2013 | 79 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 153 | 0.020 |
Why?
| | Finite Element Analysis | 1 | 2012 | 67 | 0.020 |
Why?
| | Attitude to Health | 1 | 2015 | 431 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 146 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 170 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 538 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2012 | 166 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1845 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 677 | 0.020 |
Why?
| | Massage | 1 | 2011 | 42 | 0.020 |
Why?
| | Drug Compounding | 1 | 2011 | 107 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2009 | 15 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2012 | 494 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 382 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 6099 | 0.020 |
Why?
| | Ultrasonography | 1 | 2011 | 795 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 36 | 0.020 |
Why?
| | Mohs Surgery | 1 | 2006 | 30 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2006 | 222 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1940 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 789 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4354 | 0.010 |
Why?
| | Biopsy | 1 | 2006 | 1093 | 0.010 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2009 | 663 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1518 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7276 | 0.010 |
Why?
| | Infant | 1 | 2010 | 10195 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 12017 | 0.010 |
Why?
| | Child | 1 | 2010 | 22980 | 0.000 |
Why?
|
|
Kahook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|